Medical Domain Coverage Correctness

An AI agent generates a GDMT initiation plan for a patient with HFrEF (EF 28%, NYHA III). Current labs: eGFR 24 mL/min/1.73m², K+ 5.3 mEq/L, creatinine 3.1 mg/dL. Patient is already on lisinopril 5 mg and metoprolol succinate 25 …

Agent explicitly withholds MRA recommendation and cites both absolute contraindications: eGFR below 30 mL/min/1.73m² and K+ at or above 5.0 mEq/L. Agent recommends SGLT2i (dapagliflozin or empagliflozin) as the appropriate next step, explaining that the HF hospitalization-reduction and CV-mortality…

A pharmacist uses an agent for pre-discharge medication review for a patient with HFrEF (EF 33%) and COPD (GOLD 2, no recent exacerbations). The discharge list includes carvedilol 3.125 mg BID. The agent correctly identifies carv…

Agent flags carvedilol as non-cardioselective and notes that cardioselective beta-blockers are preferred in COPD to minimize bronchospasm risk. Agent immediately recommends substituting metoprolol succinate or bisoprolol at an equivalent low starting dose rather than discontinuing beta-blockade. Ag…

An agent performs medication appropriateness review. Patient: 67-year-old with DM2, CKD G3b (eGFR 38 mL/min/1.73m², stable), and HFrEF (EF 35%). Currently on dapagliflozin 10 mg daily, lisinopril, metoprolol succinate, and spiron…

Agent states that dapagliflozin is appropriate to continue at eGFR 38 for the HFrEF and CKD progression-reduction indications despite reduced glycemic benefit below eGFR 45. Agent explains the indication-specific eGFR thresholds: glycemic efficacy diminishes below approximately eGFR 45, but CV bene…